@Article{, title={Influence of multi-drug transporter gene ABCG2 polymorphism (C421A) in clinical out care in some Iraqi chronic myeloid leukemia patients treated with imatinib mesylate}, author={Maysoon Hasan Abdul-Razq1 , Wiaam Ahmed Al-Amili2 , Abdul Hussein Moyet Al-Faisal2 , Ismail A. Abdulhassan2 , Shatha S. Jumaah3}, journal={Iraqi Journal of Biotechnology المجلة العراقية للتقانات الحياتية}, volume={16}, number={3}, pages={98-107}, year={2017}, abstract={In CML patients, Imatinib Mesylate (IM) treatment is a good choice with an excellent efficacy outcome. But unfortunately, a significant obstacle of IM resistance has emerged relating to the genetic polymorphism in drug transporter genes such as ABCG2 which effects the metabolism and pharmacokinetic IM. This study investigate the influence of ABCG2 C421A SNP in IM response among some Iraqi CML Patients (71 patients : 43 Male , 28 Female) aged between ( 20-70 ) years in chronic phase with positive Philadelphia (Ph) chromosome, including 11 newly diagnosed , and 60 treated with standard dose IM (400mg) on frontline treatment , 30 of them were IM response and 30 resistance to IM drug , on the other hand 25 apparently healthy individuals were included as control group. After the patients were informed about the details of the research, they were approved to take samples of their blood for study , 3ml of peripheral blood was withdrawn from CML patients and control groups . The frequency of homozygous mutant genotype (AA) of SNPabcg2 C421Awas significant higher in IM resistant CML patients as compared to IM good response CML patients with (O.R=1.309 and p < 0.01) . The SNP abcg2 C421A was found to contribute to the genetic susceptibility of CML when evaluated with healthy control subjects. These reconnoitering results give a reasonable cause to explore such SNPs to be used as a biomarker in prediction the response to IM treatment before getting started.

} }